Loading
IARC estimates 29,851 new cancer cases and 16,355 cancer deaths in Kazakhstan in 2024; the commonest new cancers are breast, colorectum and stomach. This page is assembled automatically from OnCo's data: 2 trials with a site there, and says what OnCo does not yet hold.
| Site | New cases | Rate | OnCo page |
|---|---|---|---|
| Breast | 4,489 | 33.9 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Colorectum | 3,598 | 14.9 | Colorectal cancer |
| Stomach | 2,951 | 12.2 | Gastric & gastro-oesophageal junction cancer |
| Trachea, bronchus and lung | 2,798 | 11.7 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Prostate | 1,706 | 18.7 | Prostate cancer |
| Cervix uteri | 1,256 | 10.2 | Cervical cancer |
| Kidney | 968 | 4.1 | Renal cell carcinoma |
| Pancreas | 963 | 4.0 | Pancreatic ductal adenocarcinoma |
| Corpus uteri | 949 | 6.9 | Endometrial cancer |
| Oesophagus | 907 | 3.7 | Oesophageal cancer |
| Site | Deaths | Rate | OnCo page |
|---|---|---|---|
| Trachea, bronchus and lung | 2,617 | 10.8 | Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer |
| Stomach | 1,895 | 7.8 | Gastric & gastro-oesophageal junction cancer |
| Colorectum | 1,722 | 7.1 | Colorectal cancer |
| Breast | 1,293 | 9.5 | Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer |
| Pancreas | 935 | 3.9 | Pancreatic ductal adenocarcinoma |
| Oesophagus | 771 | 3.2 | Oesophageal cancer |
| Liver and intrahepatic bile ducts | 733 | 3.0 | Hepatocellular carcinoma |
| Cervix uteri | 681 | 5.4 | Cervical cancer |
| Ovary | 539 | 4.0 | Ovarian cancer |
| Leukaemia | 495 | 2.2 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Chronic lymphocytic leukaemia |
| Trial | Lead sponsor | ||||
|---|---|---|---|---|---|
ALINA NCT03456076 | Phase 3 | Active not recruiting | Hoffmann-La Roche | 114 | 2026-07-15 |
| Phase 3 | Active not recruiting | Bayer | 102 | 2026-07-09 |
Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Kazakhstan, captured 2026-10-07 to 2026-10-07. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Kazakhstan is open is on the registry page, under Contacts and Locations.
OnCo holds no institution, company or person in Kazakhstan.
OnCo records approvals for United States, European Union, United Kingdom, Japan, China, Australia and India. Kazakhstan is not one of them, so no approval in OnCo speaks for it. See the approvals by region matrix for what is held.
A deep dive for Kazakhstan is ranked 44 of 60 in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.